Imlifidase
- Generic Name
- Imlifidase
- Brand Names
- Idefirix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1947415-68-0
- Unique Ingredient Identifier
- UVJ7NL8S2P
- Background
Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.
...
- Indication
Imlifidase is indicated for desensitization of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. The treatment is reserved for patients unlikely to receive a transplant under the available kidney allocation system including prioritization programs for highly sensitized patients.
- Associated Conditions
- -
- Associated Therapies
- Desensitization
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genethon
- Target Recruit Count
- 3
- Registration Number
- NCT06518005
- Locations
- 🇫🇷
Hopital Antoine BECLERE, Clamart, France
Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 10
- Registration Number
- NCT06461546
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
- Conditions
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 10
- Registration Number
- NCT05753930
- Locations
- 🇸🇪
Karolinska University Hospital, Huddinge, Stockholm, Sweden
🇪🇸Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica, Barcelona, Spain
🇫🇮HUS, Helsinki University Hospital, Helsinki, Finland
A Study With Imlifidase in Anti-GBM Disease
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 50
- Registration Number
- NCT05679401
- Locations
- 🇸🇪
Uppsala University Hospital, Department of Medical Sciences, Renal Medicine, Uppsala, Sweden
🇸🇪Karolinska University Hospital, Huddinge, Sweden
🇸🇪Linköping University Hospital, Linköping, Sweden
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
- Conditions
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 225
- Registration Number
- NCT05369975
- Locations
- 🇬🇧
Leicester General Hospital, Leicester, United Kingdom
🇦🇹Medizinische Universitaet Wien, Vienna, Austria
🇧🇪UZ Leuven - Campus Gasthuisberg, Leuven, Belgium
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 64
- Registration Number
- NCT04935177
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Georgetown Transplant Institute, Washington, District of Columbia, United States
🇺🇸Columbia University, New York, New York, United States
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 18
- Registration Number
- NCT04711850
- Locations
- 🇦🇹
Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW, Vienna, Austria
🇫🇷Hôpital Saint-Louis. Service de Néphrologie et Transplantation, Paris, France
🇫🇷Hôpital Pellegrin, Bordeaux, France
A Study of Imlifidase in Patients With Guillain-Barré Syndrome
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 30
- Registration Number
- NCT03943589
- Locations
- 🇳🇱
Erasmus Medical Centre, Rotterdam, Netherlands
🇫🇷CHU Le Kremlin-Bicêtre. Service Neurologie, Le Kremlin-Bicêtre, Paris, France
🇫🇷CHU Bordeaux - Hôpital Pellegrin Tripode, Bordeaux, France
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 30
- Registration Number
- NCT03897205
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇫🇷Hôpital Pellegrin, Bordeaux, France
🇦🇺Royal Adelaide Hospital, Adelaide, Australia
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
- Conditions
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 39
- Registration Number
- NCT03611621
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸New York University School of Medicine, New York, New York, United States
🇺🇸The Johns Hopkins Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.